Synthetic Biology & Metabolic Engineering Patents: Who Leads 2026
- 272 of 275 families sit under C12N, meaning host-chassis and genetic-circuit claims dominate over any other single technology branch.
- Filings peaked in 2018 at 58 and have not returned to that level, with the 2022 midpoint already down to 34 before the expected publication-lag drop into 2025-2026.
- Only 10 co-assignee pairs appear across the entire dataset, and the strongest reaches just four joint filings — this field is filed overwhelmingly by single entities.
Filing growth compares 2021 (42 records) with 2024 (22) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 275 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape draws on 275 patent families published between 2015 and mid-2026 that combine synthetic-biology and metabolic-engineering language with claims tied to pathway optimization, fermentation titer, genetic circuits, host chassis selection or biosensor selection, filtered to the core microorganism and fermentation IPC classes (C12N, C12P, C12N1). It captures the engineering of microbial hosts and production pathways rather than the broader synthetic-biology literature that touches medicine or agriculture only tangentially.
Filing activity in this set rose sharply through 2018 and has since cooled, which combined with an almost 99% concentration under the C12N microorganism-engineering class points to a field where the foundational chassis and circuit claims were staked out early, leaving fermentation-process refinement and a handful of adjacent applications as the more active current frontiers.
Filing trends and technology composition
Two views of the same 275-family dataset: how filing activity has moved year over year, and how the underlying IPC classification splits across microorganism engineering, fermentation chemistry and adjacent applications.
Filing activity, 2017-2026
Filings rose from zero in 2017 to a peak of 58 in 2018, sat at 34 by the 2022 midpoint, and reach only 3 by 2026 — a partial, not-yet-published final year rather than a genuine collapse in activity.
IPC subclass composition
C12N (microorganisms and genetic engineering) covers all but three of the 275 records, with C12P (fermentation and enzymatic synthesis) the dominant secondary class; bioinformatics (G16B) and fuel applications (C10L) remain minor branches.
Shares are the percentage of the 275 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Synthetic Biology and Metabolic Engineering with Eureka
This page is one run against one query. Ask Eureka your own question about synthetic biology and metabolic engineering and every answer comes back with the patent numbers behind it.
Try EurekaA recent claim worth reading in full
AI-guided synthetic biology development platform, systems, and methods
An AI-guided synthetic biology development platform, systems, and methods substantially as shown and described.Filed by X Development LLC; the broad functional language in the published abstract makes the full claim set the necessary next read for anyone assessing overlap.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20120258487A1 | Microfluidic platform for synthetic biology applications | 108 |
| 2 | US20160292355A1 | Synthetic biology tools | 39 |
| 3 | WO2021123113A1 | Production of sialylated oligosaccharide in host cells | 21 |
| 4 | WO2018156646A1 | Compositions and methods for robust dynamic metabolic control | 21 |
| 5 | CN113403334A | 一组用于酿酒酵母多拷贝整合的质粒工具包 | 18 |
| 6 | WO2012170436A1 | Synthetic biology tools | 18 |
| 7 | WO2023187109A1 | Sialyltransferases for the production of sialylated oligosaccharides | 17 |
| 8 | WO2022034080A1 | Cellular production of sialylated di- and/or oligosaccharides | 17 |
| 9 | WO2019122259A1 | Metabolic engineering | 17 |
| 10 | WO2021013708A1 | Production of fucosyllactose in host cells | 16 |
Citation counts are drawn from the searched corpus and favour earlier filings; treat them as a measure of influence rather than current commercial weight.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers actually indicate
Three read-throughs from the filing, citation and classification data that matter more than the raw counts alone.
Activity has cooled from its 2018 high
The trend line shows growth was front-loaded: a sharp rise to 58 filings in 2018, a decline to 34 by 2022, and a near-empty 2026 that reflects publication lag more than a real stop in research.
Core microorganism claims dominate the corpus
Almost the entire dataset falls under C12N, with C12P fermentation claims as the largest secondary category. Adjacent applications in medicine, fuels and bioinformatics remain minor by comparison.
Foundational platform filings still anchor the field
The most-cited records are tooling and platform patents rather than recent production claims, meaning influence in this corpus still traces back to early infrastructure filings rather than the newest chassis work.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to synthetic biology and metabolic engineering, with the prior art for and against each one.
Who is filing, and where activity has slowed
University technology-transfer offices and specialist biotech firms dominate the assignee list, but recent-year momentum data shows even the most active historical filers have gone quiet in the latest tracked year — a pattern more consistent with grant cycles and publication lag than a stopped field.
Collaboration is the exception, not the rule
Only ten co-assignee pairings appear across 275 families, and the strongest university pairing reaches just four joint filings. Most assignees in this space file independently.
Several historically active filers show no 2026 activity
University and specialist-firm assignees that filed steadily in earlier years show zero filings in the most recent tracked year, consistent with publication lag rather than an actual exit from the field.
Core chassis and circuit claims are the common ground
Nearly every assignee in this dataset, regardless of size or geography, files within the C12N microorganism-engineering class, making it the shared battleground for freedom-to-operate checks.
| Assignee | Recent year | YoY |
|---|---|---|
| Inbiose NV | 0 | -100% |
| Duke University | 0 | — |
| Manus Bio, Inc. | 0 | — |
| Jiangnan University | 0 | — |
| National University of Singapore | 0 | — |
| Plant Bioscience Limited | 0 | — |
| The Regents of the University of California | 0 | — |
| ETH Zurich | 0 | — |
Where to take this analysis
The trends above point to a field with a dense, early-staked core and a thinner set of adjacent branches — the next step is testing a specific claim or assignee against the full dataset.
Check freedom-to-operate on a host chassis
Run a specific microbial chassis or genetic-circuit design against the C12N-heavy core of this dataset before committing to a claim strategy.
Search chassis claims in EurekaTrack assignee momentum over time
Several historically active filers show zero recent-year activity; confirm whether that reflects publication lag or an actual shift in strategy before assuming the space is open.
Pull assignee timelines in EurekaDraft into the identified white space
Bioinformatics-linked strain design and fermentation-to-fuel applications remain thin relative to the core — test a draft claim there for prior art density.
Test white-space claims in EurekaFrequently asked questions
The assignee ranking in this dataset is led by a mix of university technology-transfer offices and specialist biotech firms rather than a single dominant corporate filer. Several of the most active recent assignees, including university-affiliated groups, show no filings in the latest tracked year, which suggests filing activity is cyclical or tied to specific research grants rather than continuous. Co-assignee filings are relatively rare across the set, with only ten pairs identified and the strongest pairing reaching four joint filings, so most work here is filed by single entities rather than joint ventures.
Filings climbed from zero in 2017 to a peak of 58 in 2018, then declined toward a 2022 midpoint of 34 and dropped further into the low single digits by 2026. Because patent publication typically lags filing by around 18 months, the 2025-2026 figures are understated and should not be read as a real fall-off in research activity. The more reliable signal is that filing density has not returned to its 2018 peak, meaning the field's core claim space around host-chassis and pathway-optimization methods was largely staked out early.
The smaller IPC branches — bioinformatics-supported strain design (G16B, 9 records) and fermentation-to-fuel applications (C10L, 3 records) — carry far fewer filings than the core microorganism and fermentation classes, indicating less-claimed territory. Therapeutic-activity applications (A61P, 10 records) and medicinal preparations (A61K, 13 records) are also thinner than the core, suggesting synthetic-biology methods have not been as heavily claimed for direct therapeutic use as for chassis and production work. A first filing combining a computational selection step with a specific host and measurable fermentation outcome would sit in relatively open space.
WO2025255010A1, filed by X Development LLC in December 2025, describes an AI-guided synthetic biology development platform, systems and methods. It represents a shift toward claiming the design-and-selection workflow layer rather than a specific organism, pathway or genetic circuit, which is where most of the rest of the dataset's claims sit. Because it is the most recent representative record in the set, it signals where new filing activity may be heading even though the broader 2025-2026 filing numbers remain small and likely understated due to publication lag.
The United States receives the largest share of filings in this dataset at 85, followed by the WIPO PCT route at 41 and the European Patent Office at 36. Australia, China and Israel each show smaller but notable counts, indicating that applicants pursuing this technology tend to prioritize US protection first and use PCT filings to keep international options open before committing to specific national or regional phases. This pattern is typical of biotech fields where the highest-value commercial markets and the most active research funding are concentrated in the US and Europe.
Research Synthetic Biology and Metabolic Engineering in depth with Eureka
Go past this page: query the whole synthetic biology and metabolic engineering corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.